Changes

Jump to navigation Jump to search

NIH royalties (view source)

Revision as of 00:58, April 11, 2022

404 bytes added ,  00:58, April 11, 2022
Since 2017, the royalty income has been declining, which have increased the pressure at the NIH to push for patentable patents rather than inexpensive medications for treating COVID-19.
'''NIH royalties''' on its [[patent]]s can enrich the bureaucracy and its officers.

Since 2017, the royalty income has been declining, which have increased the pressure at the [[NIH]] to push for patentable patents rather than inexpensive medications for treating [[COVID-19]].<ref>https://www.ott.nih.gov/metrics/royalty-income</ref>
== References ==
{{reflist}}
{{coronavirus}}
[[category:patent law]]
Aschlafly
Anthony, Irenaeus, Siteadmin, apieditor, Bureaucrats, Check users, nsAm_Govt_101RO, nsAm_Govt_101RW, nsAm_Govt_101_ta, nsJudgesRO, nsJudgesRW, nsJudges_talkRO, nsJudges_talkRW, nsTeam2RO, nsTeam2RW, nsTeam2_talkRO, nsTeam2_talkRW, oversight, Administrators
126,204

edits

Retrieved from "https://www.conservapedia.com/Special:MobileDiff/1851034"

Navigation menu